Abstract
A field trial with a new HIB conjugate vaccine, PRP-D, was initiated in Finland in January 1986. Infants born after October 1, 1985 are offered PRP-D in an open study according to their birthdate. Those born on odd days receive PRP-D at 3, 4, 6 and 14 months and those born on even days, at 24 months. All children receive the routine vaccinations: DPT at 3, 4, 5 and 24 months, IPV at 6, 12 and 24 months and MMR at 14 months. A cohort of these children has been followed serologically. Geometric mean antibody concentrations of anti-PRP antibody by radioimmunoassay at the ages of 3, 4, 6 and 7 months are 0.12, 0.10, 0.10 and 0.45 ug/ml respectively. PRP-D does not have an adverse effect on the antibody response to the routine vaccines. During the first 10 months over 90% of infants in the country have been enrolled. Side effects (local soreness, fever, irritability and other minor reactions) have been rare in the over 20,000 children vaccinated with PRP-D. Based on age-specific attack rates in Finland we have calculated that if the protective efficacy of PRP-D is over 50%, we will be able to demonstrate it by April 1987.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eskola, J., Peltola, H., Takala, A. et al. H. INFLUENZAE B (H.I.B.) CAPSULAR POLYSACCHARIDE-DIPHTHERIA TOXOID CONJUGATE VACCINE (PRP-D): A FIELD TRIAL IN FINLAND. Pediatr Res 21 (Suppl 4), 324 (1987). https://doi.org/10.1203/00006450-198704010-00940
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-00940